Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients)

Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients)

Abstract Background There is limited evidence over the real‐life secukinumab survival in psoriatic patients, especially in the long‐term bio‐naïve subjects, and to date biological treatments have been assessed in patients with a chronic and recalcitrant psoriasis. It has been hypothesised that early...

Full description

Bibliographic Details
Main Authors: Francisco Javier Melgosa Ramos, Almudena Mateu Puchades, Santiago Guillén Climent, Marta Galarreta Pascual, Marina Saéz Belló, María Angels Martínez Ferrer, Fernando Toledo Alberola, Jorge Magdaleno Tapial, Jose Luís Sánchez Carazo, Javier Matáix Díaz, Luca Schneller‐Pavelescu Apetrei, Laura García Fernández, Iris González Villanueva, Isabel Belinchón Romero, Sergio Martín Jiménez, Sergio Santos Alarcón
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:JEADV Clinical Practice
Subjects:
bio‐naïve
IL‐17 inhibitors
psoriasis
real‐world experience
secukinumab
Online Access:https://doi.org/10.1002/jvc2.185

Internet

https://doi.org/10.1002/jvc2.185

Similar Items